Skip to main content

Table 2 TCGA actionable landscape in different publications

From: From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards

 

Standard therapy

Clinical trials

Preclinical

Total

Number of TCGA samples

Databases used by the study

Label

Off-label

Label

Off-label

Label

Off-label

   

MTB

9.9 (A1)

22.7 (B1)

64.1 (A2)

89 (B2)

90.6 (A3)

94.1 (B3)

94

3184

GDKD, CIViC, TARGET

Dienstmann et al. 2015 [20]

11 (5)

39 (4)

75 (3)

93 (1-2)

93

4392

GDKD

Rubio-Perez et al. 2015 [19]

5.9

40.2

73.3

73.3

4068

Rubio-Perez et al. 2015

Chakravarty et al. 2017 [18]

7.5 (1–2A)

16 (2B)

26 (3A)

41 (3B)

41

5983

OncoKB

  1. The table shows the cumulative percentages of patients with actionable variants identified at different levels. The name of the levels used in each publication are specified in parentheses. The studies being compared are: MTB (this publication), Chakravarty et al. 2017 [18], Dienstmann et al. 2015 [20], and Rubio-Perez et al. 2015 [19]